## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.97 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (43% of avg), momentum weakening (-3.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($183.40)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. BD Launches Portable PureWick Device to Help Women Manage Urinary Incontinence on the Go**
- Source: The Healthcare Technology Report. | 20251201T132120 | Bullish | Relevance: 99%
- BD has expanded its PureWick™ portfolio with a new portable urine collection system for individuals managing urinary incontinence, particularly wheelchair users, offering greater flexibility outside the home. The battery-powered device utilizes external suction technology in a lightweight, mobile form factor with up to eight hours of battery life. This innovation aims to enhance confidence and independence by providing a discreet, accessible solution for managing incontinence in daily activities and travel.

**2. Is Becton, Dickinson and Company Stock Underperforming the Nasdaq?**
- Source: Markets Financial Content | 20251201T092900 | Neutral | Relevance: 98%
- Becton, Dickinson and Company (BDX) has underperformed the Nasdaq Composite, with its stock slipping 23% from its 52-week high and showing weaker gains over three months, YTD, and the past 52 weeks. Despite this, the company's Q4 results exceeded EPS expectations, and analysts maintain a "Moderate Buy" rating with a potential upside. BDX's underperformance is attributed to macro challenges, including vaccine demand and biosciences research headwinds.

**3. Does Europe’s First CE-Approved Surgical Irrigation System Shift the Bull Case for BD (BDX)?**
- Source: Simply Wall Street | 20251130T063607 | Bullish | Relevance: 98%
- BD (Becton, Dickinson and Company) recently launched the BD Surgiphor Surgical Wound Irrigation System in Europe, the first of its kind to receive CE approval, enhancing its infection-prevention portfolio. This move aligns with BD's strategy to accelerate innovation and pipeline growth amidst operational reorganization and planned business separations. Investors are encouraged to consider diverse perspectives on BD's valuation, which projects $24.7 billion in revenue and $2.8 billion in earnings by 2028.

**4. Fitch Rates GE Healthcare's Senior Unsecured Notes 'BBB'**
- Source: TradingView | 20251201T142617 | Somewhat-Bullish | Relevance: 62%
- Fitch Ratings has assigned 'BBB' ratings to GE HealthCare Technologies Inc.'s senior unsecured notes, with proceeds primarily intended for the acquisition of Intelerad Medical Systems, Inc. The rating is supported by GEHC's solid standalone operating performance, consistent free cash flow generation, and leading market position in the medical imaging space, despite geopolitical risks and significant pension benefit obligations. Fitch forecasts revenue growth and margin expansion in the coming years, driven by innovation and strategic acquisitions.

**5. AlphaCore Capital LLC Purchases Shares of 1,307 iShares MSCI Intl Momentum Factor ETF $IMTM**
- Source: Defense World | 20251201T042144 | Neutral | Relevance: 58%
-  AlphaCore Capital LLC has acquired a new position in iShares MSCI Intl Momentum Factor ETF (NYSEARCA:IMTM), purchasing 1,307 shares valued at approximately $60,000. Other institutional investors like JPMorgan Chase & Co., Archvest Wealth Advisors Inc., Weaver Consulting Group, Bell Investment Advisors Inc, and Rockefeller Capital Management L.P. also modified their holdings in IMTM. The iShares MSCI Intl Momentum Factor ETF, launched in 2015 and managed by BlackRock, tracks an index of large- and mid-cap stocks from developed countries outside the US.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.97 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.9B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.97 |
| Forward P/E | 12.1 |
| Current P/E | 12.8 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.1% to 0.9% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 (-1.3%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (0.52), confirming momentum. RSI neutral at 55. Volume at 43% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.92% (CS: 62) | Neutral |
| RSI_14 | 55.0 | Neutral |
| MACD Histogram | 0.52 | Bullish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.023x | Above |
| vs SMA200 | 0.999x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $191.82
- **Stop Loss:** $183.40 (4.4% risk)
- **Target:** $208.66 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 89
- **Position Value:** $17,071.98
- **Portfolio %:** 17.07%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*